RT Journal Article
SR Electronic
T1 The Gut Microbiome Strongly Mediates the impact of Lifestyle combined variables on Cardiometabolic Phenotypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.12.24301195
DO 10.1101/2024.01.12.24301195
A1 Adriouch, Solia
A1 Belda, Eugeni
A1 Swartz, Timothy D
A1 Forslund, Sofia
A1 Le Roy, Tiphaine
A1 Prifti, Edi
A1 Aron-Wisnewsky, Judith
A1 Chakaroun, Rima
A1 Nielsen, Trine
A1 Andrikopoulos, Petros
A1 Chechi, Kanta
A1 Puig-Castellví, Francesc
A1 Froguel, Philippe
A1 Holmes, Bridget
A1 Alili, Rohia
A1 Andreelli, Fabrizio
A1 Soula, Hedi
A1 Salem, Joe-Elie
A1 Falony, Gwen
A1 Vieira-Silva, Sara
A1 Galazzo, Gianluca
A1 MetaCardis Consortium
A1 Raes, Jeroen
A1 Bork, Peer
A1 Stumvoll, Michael
A1 Pedersen, Oluf
A1 Ehrlich, S. Dusko
A1 Dumas, Marc-Emmanuel
A1 Oppert, Jean-Michel
A1 Dao, Maria Carlota
A1 Zucker, Jean-Daniel
A1 Clément, Karine
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2024.01.12.24301195.abstract
AB Individual lifestyle factors moderately impact the gut microbiome and host biology. This study explores whether their combined influence significantly alters the gut microbiome and determines the mediating role of the gut microbiome in the links between lifestyle and phenomes. Analyzing 1,643 individuals from the Metacardis European study, we created a non-exhaustive composite lifestyle score (QASD score) incorporating diet quality and diversity, physical activity and smoking. This score shows higher explanatory power for microbiome composition variation compared to individual lifestyle variables. It positively associates with microbiome gene richness, butyrate-producing bacteria, and serum metabolites like Hippurate linked metabolic health. It inversely associates with Clostridium bolteae and Ruminococcus gnavus, serum branched-chain amino acids and dipeptides observed in chronic diseases. Causal inference analyses found 135 cases where the microbiome mediates >20% of QASD score effects on host metabolome. Microbiome gene richness also emerged as a strong mediator in the QASD score’s impact on markers of host glucose metabolism (27.3% of the effect on HOMA- IR), despite bidirectional associations between the microbiome and clinical phenotypes. This study emphasizes the importance of combining lifestyle factors to understand their collective contribution to the gut microbiota and the mediating effects of the gut microbiome on the impact of lifestyle on host metabolic phenotypes and metabolomic profiles.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://clinicaltrials.gov/study/NCT02059538?cond=NCT02059538&term=NCT02059538&intr=NCT02059538&rank=1 Funding StatementThis work was supported by European Union s Seventh Framework Programme for research technological development and demonstration under grant agreement HEALTH-F4-2012-305312 (METACARDIS). Funding supports were also obtained from Leducq Foundation(17CVD01), JPI-Microdiet study (2017-01996_3). Part of the work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG): SFB 1052 (project B1) the Fondation pour la Recherche Medicale (FDT201904008276 FDT202106012793) and the French Agency of Research (ANR-CAPTOR, ANR-DeepIntegromics)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee at the Medical Faculty at the University of Leipzig Germany (application number: 047-13-28012013) the ethical committees of the Capital Region of Denmark (H-3-2013-145) and the ethics committee Comite de Protection des Personnes (CPP) Ile-de-France III no.IDRCB2013-A00189-36 in France and was registered at https://clinicaltrials.gov/ (NCT02059538). The observational cohort design complied with all relevant ethical regulations, aligning with the Helsinki Declaration and in accordance with European privacy legislation. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw shotgun sequencing data that support the findings of this study have been deposited in the European Nucleotide Archive with accession codes PRJEB37249, PRJEB38742, PRJEB41311, PRJEB46098 and PRJEB71898, with public access. Metabolome data have been uploaded to Metabolights and MassIVE with respective accession numbers—that is, serum NMR and urine NMR with accession number MTBLS3429.